Form 4: NeuroBo Pharmaceuticals CEO Kim Hyung Heon Reports Tax Liability Stock Disposal
SEC Form 4 Filing
CEO Kim Hyung Heon of NeuroBo Pharmaceuticals reports disposition of shares to cover tax obligations related to vesting restricted stock units.
Summary
- On August 11, 2024, Kim Hyung Heon, CEO and President of NeuroBo Pharmaceuticals, reported a transaction involving common stock.
- 11,467 shares were disposed of to cover tax liabilities related to the vesting of restricted stock units.
- The shares were withheld by the issuer at a price of $3.6 based on the closing price on August 9, 2024.
- Following the transaction, Kim Hyung Heon beneficially owns 66,666 shares of common stock.
- The total number of securities beneficially owned has been adjusted to reflect the Issuer's completion of a 1-for-8 reverse stock split on December 20, 2023.
Sentiment
Score: 5
Explanation: This Form 4 filing is a neutral event related to standard executive compensation practices and tax obligations.
Industry Context
This is a routine filing related to executive compensation and tax obligations. It doesn't necessarily indicate a change in the company's overall prospects.
Key Dates
| Date | Description |
|---|---|
| December 20, 2023 | Issuer's completion of a 1-for-8 reverse stock split |
| August 9, 2024 | Issuer's closing price used to calculate tax liabilities |
| August 11, 2024 | Date of transaction (stock disposal for tax liabilities) |
| August 13, 2024 | Date of signature |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.